Voyageur Pharmaceuticals Ltd.
VYYRF
$0.08
-$0.02-20.00%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.11M | 982.70K | 835.50K | 886.80K | 908.10K |
| Depreciation & Amortization | 1.20K | 1.30K | 1.40K | 1.50K | 1.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11M | 984.00K | 836.90K | 888.30K | 909.70K |
| Operating Income | -1.11M | -984.00K | -836.90K | -888.30K | -909.70K |
| Income Before Tax | -1.25M | -1.13M | -962.00K | -1.01M | -1.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.25 | -1.13 | -0.96 | -1.01 | -1.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.25M | -1.13M | -962.00K | -1.01M | -1.04M |
| EBIT | -1.11M | -984.00K | -836.90K | -888.30K | -909.70K |
| EBITDA | -1.11M | -982.70K | -835.50K | -886.80K | -908.10K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 550.46M | 543.76M | 537.02M | 530.84M | 521.88M |
| Average Diluted Shares Outstanding | 550.46M | 543.76M | 537.02M | 530.84M | 521.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |